Announcements Trials
Browse Landscape

Status

No longer available 1Available 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 482Observational 10Expanded_access 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2

Interventions

3-Iodobenzylguanidine 6Magnetic Resonance Spectroscopy 5Amifampridine 5gallium 68 PSMA-11 4fludarabine phosphate 3Cyclophosphamide 3pembrolizumab 2fluorodopa F 18 2fludarabine 2carbon-11 acetate 2Whole-Body Irradiation 2Oxaliplatin 2Ga(III)-DOTATOC 2Fluorouracil 2Bortezomib 2Bone Marrow Transplantation 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2venetoclax 1veliparib 1ulocuplumab 1trametinib 1selinexor 1ponatinib 1pegfilgrastim 1omburtamab I-131 1nirogacestat 1neratinib 1navitoclax 1motexafin gadolinium 1mifamurtide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Expanded_access × Bortezomib × Clear all
NCT02666209 2017-08-28

Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma

Dana-Farber Cancer Institute

No longer available
Plasma cell

Multiple Myeloma

NCT01250808 2010-12-01

Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy

Peking University

Available
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡